Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition comprising telmisartan salt and calcium ion antagonist

The technology of a calcium ion antagonist, telmisartan, is applied in the directions of drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., and can solve the problems of poor solubility, unsatisfactory results, poor bioavailability, etc. question

Inactive Publication Date: 2011-12-07
王丽燕
View PDF26 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Patent Documents 2 and 3 disclose pharmaceutical compositions comprising telmisartan and amlodipine. Since telmisartan exists in acid form, its solubility is not good between pH 1 and 7, so its bioavailability Poor, unsatisfactory results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising telmisartan salt and calcium ion antagonist
  • Pharmaceutical composition comprising telmisartan salt and calcium ion antagonist
  • Pharmaceutical composition comprising telmisartan salt and calcium ion antagonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0088] Example 1: Tablets Comprising Telmisartan Sodium and Amlodipine Besylate

[0089] Name of raw material Dose 1 (mg) Dose 2 (mg) Dose 3 (mg) Dose 4(mg) Telmisartan Sodium 10.00 20.00 40.00 80.00 Amlodipine 6.94 6.94 6.94 6.94 microcrystalline cellulose 3.96 14.86 36.66 80.26 Povidone K30 2.50 5.00 10.00 20.00 Carboxymethyl Starch Sodium 0.82 1.65 3.30 6.60 Micropowder silica gel 0.20 0.40 0.80 1.60 Magnesium stearate 0.58 1.15 2.30 4.60 Sheet weight 25.00 50.00 100.00 200.00

[0090] Preparation:

[0091] (A) Telmisartan sodium and amlodipine besylate were dried at 80° C. for 6 hours respectively, crushed through an 80 mesh sieve, and then mixed uniformly in a mixer by an equal addition method;

[0092] (B) Microcrystalline cellulose, povidone K30, sodium carboxymethyl starch, micropowder silica gel and magnesium ste...

Embodiment 2

[0098] Example 2: Tablets Comprising Telmisartan Sodium and Amlodipine Besylate

[0099] Name of raw material Dose 1 (mg) Dose 2 (mg) Dose 3 (mg) Dose 4(mg) Telmisartan Sodium 20.00 40.00 80.00 160.00 Amlodipine 1.74 3.47 6.94 13.88 Optimized Microcrystalline Cellulose 8.48 16.96 33.91 67.82 Povidone K30 5.00 10.00 20.00 40.00 Carboxymethyl Starch Sodium 1.50 3.00 6.00 12.00 Micropowder silica gel 0.41 0.82 1.65 3.30 Magnesium stearate 0.38 0.75 1.50 3.00 Sheet weight 37.50 75.00 150.00 300.00

[0100] Preparation:

[0101] (A) Telmisartan sodium and amlodipine besylate were dried at 80° C. for 6 hours respectively, crushed through an 80 mesh sieve, and then mixed uniformly in a mixer by an equal addition method;

[0102] (B) Dry the optimized microcrystalline cellulose, povidone K30, sodium starch glycolate, micropowder ...

Embodiment 3

[0106] Example 3: Tablets Comprising Telmisartan Sodium and Amlodipine Besylate

[0107] Name of raw material Dose 1 (mg) Dose 2 (mg) Dose 3 (mg) Dose 4(mg) Telmisartan Sodium 10.00 20.00 40.00 80.00 Amlodipine 6.94 6.94 6.94 6.94 calcium carbonate 3.95 14.85 36.64 80.21 Povidone K30 2.50 5.00 10.00 20.00 sodium starch glycolate 0.55 1.10 2.20 4.40 sodium starch glycolate 0.28 0.55 1.10 2.20 Micropowder silica gel 0.20 0.41 0.82 1.65 Magnesium stearate 0.58 1.15 2.30 4.60 Sheet weight 25.00 50.00 100.00 200.00

[0108] Preparation:

[0109] (A) Telmisartan sodium and amlodipine besylate were dried at 80°C for 6 hours respectively, crushed through a 100-mesh sieve, and then mixed uniformly in a mixer by an equal addition method;

[0110](B) Calcium carbonate, povidone K30, sodium carboxymethyl starch added...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Hardnessaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a kind of pharmaceutical composition, it comprises telmisartan salt and calcium ion antagonist or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier; Described telmisartan salt is selected from telmisartan Sodium salt, potassium salt, calcium salt, magnesium salt or amine salt of sartan, described calcium ion antagonist is selected from amlodipine, lacidipine, cilnidipine, lercanidipine, nisoldipine, nica Dipine, azedipine, barnidipine, manidipine, benidipine, verapamil, diltiazem, or a pharmaceutically acceptable salt thereof. The composition is used for preventing, delaying progress or treating patients with hypertension, angina pectoris, atherosclerosis, stroke, cardiac insufficiency, dyslipidemia, diabetes, renal function damage or hypertension accompanied by Alzheimer's disease, reducing Reduce the morbidity and / or mortality of cardiovascular and cerebrovascular diseases, reduce adverse drug reactions, and improve patients' compliance with medication.

Description

technical field [0001] The present invention relates to a kind of novel pharmaceutical composition, it comprises telmisartan salt and calcium ion antagonist or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier, is used for preventing, delaying progress or treating patient hyperplasia Blood pressure, angina pectoris, atherosclerosis, stroke, myocardial infarction, cardiac insufficiency, dyslipidemia, diabetes, renal dysfunction or hypertension accompanied by Alzheimer's disease belong to the field of medical technology. Background technique [0002] Due to social and economic development and changes in people's lifestyles, the prevalence of hypertension in my country has continued to increase. It is estimated that there are 160 million hypertensive patients nationwide. At present, one person dies of cardiovascular and cerebrovascular diseases every 15 seconds in my country, and the total morbidity and mortality of cardiovascular and cerebrovascular ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/4184A61P9/12A61P9/10A61P9/04A61P9/14A61P3/10A61P3/06A61P13/12A61P27/06A61P25/28
Inventor 王丽燕
Owner 王丽燕
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com